| Literature DB >> 32722327 |
Mariaimmacolata Preianò1, Rocco Savino2, Chiara Villella1, Corrado Pelaia1, Rosa Terracciano3.
Abstract
Given its intrinsic nature, gingival crevicular fluid (GCF) is an attractive source for the discovery of novel biomarkers of periodontal diseases. GCF contains antimicrobial peptides and small proteins which could play a role in specific immune-inflammatory responses to guarantee healthy gingival status and to prevent periodontal diseases. Presently, several proteomics studies have been performed leading to increased coverage of the GCF proteome, however fewer efforts have been done to explore its natural peptides. To fill such gap, this review provides an overview of the mass spectrometric platforms and experimental designs aimed at GCF peptidome profiling, including our own data and experiences gathered from over several years of matrix-assisted laser desorption ionization/time of flight mass spectrometry (MALDI-TOF MS) based approach in this field. These tools might be useful for capturing snapshots containing diagnostic clinical information on an individual and population scale, which may be used as a specific code not only for the diagnosis of the nature or the stage of the inflammatory process in periodontal disease, but more importantly, for its prognosis, which is still an unmet medical need. As a matter of fact, current peptidomics investigations suffer from a lack of standardized procedures, posing a serious problem for data interpretation. Descriptions of the efforts to address such concerns will be highlighted.Entities:
Keywords: MALDI-TOF; antimicrobial peptides; gingival crevicular fluid; mass spectrometry; peptides; peptidomics; periodontal diseases
Year: 2020 PMID: 32722327 PMCID: PMC7432128 DOI: 10.3390/ijms21155270
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Scheme 1Overview of the main informational data extrapolated by peptidomics experiments on gingival crevicular fluid (GCF). Peptidomics workflow, without a digestion step, allows to preserve the endogenous information of peptides from GCF, including post-translational modifications and proteolytic products.
Gingival crevicular fluid (GCF) peptidomics profiling studies.
| Ref. | Collection | Storage Conditions | Protein Quantitation | MS | MS-Approach | Naturally Occurring Peptides &Small Proteins |
|---|---|---|---|---|---|---|
| Lundy et al. [ | Paper strips/sodium phosphate containing NaCl; NO PIC; RP-HPLC. | −70 °C, time not specified. | Yes | Not required (a) | N-terminal aminoacid sequencing and LC-MS | S100-A8 |
| Diamond et al. [ | Periopaper strips/5% acetic acid; NO PIC; ProteinChip. | Not specified. | No | No | SELDI-TOF | α-defensins 1–3, hBD-1 derived peptides, hBD-2 |
| Dommisch et al. [ | Periopaper strips/5% acetic acid; NO PIC; ProteinChip. | Not specified. | Yes (b) | No | SELDI-TOF | α-defensins 1–3, Cathelicidin antimicrobial peptide LL-37 |
| Lundy et al. [ | Periopaper strips/sodium phosphate containing NaCl; NO PIC; Unfractionated. | −80 °C, time not specified. | Yes | No | MALDI-TOF | α-defensins 1–3 |
| Wen et al. [ | Paper points/2.5% TFA; NO PIC; Unfractionated. | −80 °C, time not specified. | No | Yes | MALDI-TOF | |
| Ngo et al. [ | Glass microcapillary tubes/water or 0.1% TFA for HPLC fractionation; NO PIC; ZipTips or RP-HPLC. | −70 °C, time not specified. | No | No | MALDI-TOF/TOF | α-defensins 1–3, |
| Ngo et al. [ | Glass microcapillary tubes/GCF (0.2–1.5 µL) was dispensed with 2.5% TFA; NO PIC; ZipTips. | −70 °C, time not specified. | No | Yes | MALDI-TOF | Attachment loss sites vs. stable sites ( |
| Preianò et al. [ | Paper points, Paper strips/2.5% TFA or 5% acetic acid; PIC and NO PIC; Unfractionated. | GCF was immediately analyzed by MS. | Yes | Yes | MALDI-TOF/TOF | α-defensins 1–4, Thymosin β4 |
| Preianò et al. [ | Paper strips/2.5%TFA; PIC and NO PIC; Unfractionated. | −20 °C/1 or 3 months, −80 °C/1 or 3 months and immediately analyzed | Yes | Yes | MALDI-TOF/TOF | α-defensins 1–4, hBD-2, Thymosin β4, S100-A8 and its oxidized forms, S100-A9 and its isoforms, Lysozyme C |
| Preianò et al. [ | Paper strips/2.5%TFA; PIC and NO PIC, Unfractionated. | −20 °C/1 month, −80 °C/1 month and immediately analyzed. | Yes | Yes | MALDI-TOF/TOF | α-defensins 1–3, hBD-2, C-36 peptide of AAT, Thymosin β4, Thymosin β10, S100-A8 and its oxidized forms, S100-A9 and its isoforms, Lysozyme C |
| Tang et al. [ | Paper strips/phosphate-buffered saline; NO PIC; Weak cation exchange magnetic beads. | −80 °C, time not specified (c). | No | Yes | MALDI-TOF | Haptoglobin derived peptide and other unidentified peptides: |
| Antezack et al. [ | Paper points/HPLC-grade water; NO PIC; Unfractionated. | +4 °C and analyzed within 24 to 48 h. | No | Yes | MALDI-TOF | |
| Pisano et al. [ | Paper cones/0.2% TFA aqueous solution; NO PIC; RP-HPLC. | −80 °C, time not specified. | No | Yes | ESI-Ion Trap | α-defensins 1–4, Statherin, Peptide PB, Cystatin A |
| Inzitari et al. [ | Paper cones/0.2% TFA aqueous solution; NO PIC; RP-HPLC. | Storage conditions not specified. | Yes | Yes | ESI-Ion Trap | Thymosin β4, Thymosin β4 sulfoxide, Thymosin β10 |
| Dassatti et al. [ | Paper cones/Buffer not specified; Use of PIC not specified; RP-HPLC. | −80 °C, time not specified. | No | Yes | ESI-Ion Trap/ | α-defensins 1–4, Thymosin β4, Thymosin β4 fragment (21–44), Thymosin β10, Fibrinopeptide A, Fibrinopeptide A fragments (21–35) and (22–35), Fibrinopeptide B |
(a) Peak normalization is not required as it is a targeted study. (b) Protein quantitation: samples from healthy periodontal sites served as internal control (baseline) for quantitative analysis. (c) After storage at −80 °C, GCF samples were fractioned using a weak cation exchange magnetic bead kit and then immediately analyzed on MALDI-TOF or stored at −20 °C and analyzed within 24 h.
Naturally occurring peptides found in gingival crevicular fluid (GCF) from different study groups. Expression levels are shown as increased (↑) or decreased (↓), as determined by the referred investigation in relation to the appropriate control group. H = Healthy, G = Gingivitis, P = periodontitis, CP = Chronic periodontitis.
| Naturally Occurring Peptides | Methods | Study Groups | Study Groups and Protein Expression Level | Ref. |
|---|---|---|---|---|
| C-36 AAT | MALDI-TOF | H (10) vs. G (10) | ↓H/↑G * | Preianò et al. [ |
| Cathelicidin antimicrobial peptide LL-37 | SELDI-TOF | H sites ( | ↓H sites/↑G sites in H * | Dommisch et al. [ |
| Fibrinopeptide A | ESI-Ion Trap/Orbitrap | G and P sites in women after pregnancy (10) and not pregnant women as H controls (10). | ↓H/↑P sites * | Dassatti et al. [ |
| Fibrinopeptide A fragment (21–35) | ESI-Ion Trap/Orbitrap | G and P sites in women after pregnancy (10) and not pregnant women as H controls (10). | ↓H/↑P sites * | Dassatti et al. [ |
| Fibrinopeptide A fragment (22–35) | ESI-Ion Trap/Orbitrap | G and P sites in women after pregnancy (10) and not pregnant women as H controls (10). | ↓H/↑P sites * | Dassatti et al. [ |
| Fibrinopeptide B | ESI-Ion Trap/Orbitrap | G and P sites in women after pregnancy (10) and not pregnant women as H controls (10). | ↓H/↑P sites * | Dassatti et al. [ |
| Haptoglobin derived peptide | MALDI-TOF | CP (17) and H (16). | ↓H/↑CP * | Tang et al. [ |
| hBD-1 | SELDI-TOF | Patients with mild to moderate gingival inflammation (2). | ↑mild gingival inflammation/↓moderate gingival inflammation | Diamond et al. [ |
| hBD-2 | SELDI-TOF | Patients with mild to moderate gingival inflammation (2). | ↓mild gingival inflammation/↑moderate gingival inflammation | Diamond et al. [ |
| HNP-1 | SELDI-TOF | Patients with mild to moderate gingival inflammation (2). | ↓mild gingival inflammation/↑moderate gingival inflammation | Diamond et al. [ |
| SELDI-TOF | H sites ( | ↓H sites/↑G sites in H | Dommisch et al. [ | |
| MALDI-TOF | P(11) and H (12) | ↑H/↓P | Lundy et al. [ | |
| ESI-Ion Trap/Orbitrap | G and P sites in women after pregnancy (10) and not pregnant women as H controls (10). | ↓H/↑P sites * | Dassatti et al. [ | |
| HNP-2 | SELDI-TOF | Patients with mild to moderate gingival inflammation (2) | ↓mild gingival inflammation/↑moderate gingival inflammation | Diamond et al. [ |
| SELDI-TOF | H sites ( | ↓H sites/↑G sites in H | Dommisch et al. [ | |
| MALDI-TOF | P (11) and H (12) | ↑H/↓P | Lundy et al. [ | |
| MALDI-TOF | H (10) vs. G (10) | ↓H/↑G * | Preianò et al. [ | |
| ESI-Ion Trap/Orbitrap | G and P sites in women after pregnancy (10) and not pregnant women as H controls (10). | ↓H/↑P sites * | Dassatti et al. [ | |
| HNP-3 | SELDI-TOF | Patients with mild to moderate gingival inflammation (2). | ↓mild gingival inflammation/↑moderate gingival inflammation | Diamond et al. [ |
| MALDI-TOF | P (11) and H (12) | ↑H/↓P | Lundy et al. [ | |
| ESI-Ion Trap/Orbitrap | G and P sites in women after pregnancy (10) and not pregnant women as H controls (10). | ↓H/↑P sites * | Dassatti et al. [ | |
| HNP-4 | ESI-Ion Trap/Orbitrap | G and P sites in women after pregnancy (10) and not pregnant women as H controls (10). | ↓H/↑P sites | Dassatti et al. [ |
| S100-A8 | N-terminal amino acid sequencing and LC-MS | H, G and P sites in patients with P (15) and H sites in H subjects (5). | ↓H/↑G sites in P * | Lundy et al. [ |
| S100-A9 | MALDI-TOF | H (10) vs. G (10) | ↑H/↓G * | Preianò et al. [ |
| S100-A9 Glutathionylated | MALDI-TOF | H (10) vs. G (10) | ↓H/↑G * | Preianò et al. [ |
| Thymosin β-4 | MALDI-TOF | H (10) vs. G (10) | ↑H/↓G * | Preianò et al. [ |
| ESI-Ion Trap/Orbitrap | G and P sites in women after pregnancy (10) and not pregnant women as H controls (10). | ↑H/↓P sites * | Dassatti et al. [ | |
| Thymosin β-4 fragment (21–44) | ESI-Ion Trap/Orbitrap | G and P sites in women after pregnancy (10) and not pregnant women as H controls (10). | ↓H/↑P sites * | Dassatti et al. [ |
| Thymosin β-10 | ESI-Ion Trap/Orbitrap | G and P sites in women after pregnancy (10) and not pregnant women as H controls (10). | ↑H/↓P sites * | Dassatti et al. [ |
* Statistically significant difference.